1. Home
  2. KTF vs IMNM Comparison

KTF vs IMNM Comparison

Compare KTF & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DWS Municipal Income Trust

KTF

DWS Municipal Income Trust

HOLD

Current Price

$9.03

Market Cap

365.1M

Sector

Finance

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$21.42

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KTF
IMNM
Founded
1988
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
365.1M
1.8B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
KTF
IMNM
Price
$9.03
$21.42
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$31.44
AVG Volume (30 Days)
103.3K
2.7M
Earning Date
01-01-0001
11-06-2025
Dividend Yield
3.54%
N/A
EPS Growth
N/A
N/A
EPS
0.39
N/A
Revenue
N/A
$9,679,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$23.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.40
$5.15
52 Week High
$9.12
$25.30

Technical Indicators

Market Signals
Indicator
KTF
IMNM
Relative Strength Index (RSI) 34.74 59.04
Support Level $9.08 $19.37
Resistance Level $9.16 $25.30
Average True Range (ATR) 0.06 1.67
MACD -0.01 0.03
Stochastic Oscillator 15.25 55.24

Price Performance

Historical Comparison
KTF
IMNM

About KTF DWS Municipal Income Trust

DWS Municipal Income Trust is a closed-ended fixed income mutual fund launched and managed by Deutsche Investment Management Americas, Inc. The company invests in the fixed income markets of the United States. The fund invests in investment-grade tax-exempt municipal securities which are exempt from federal income tax. The fund benchmarks the performance of its portfolio against the Barclays Municipal Bond Index. The Fund invests in various states, such as Texas, Florida, Pennsylvania, Illinois, and California.

About IMNM Immunome Inc.

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

Share on Social Networks: